US equities
|
NVDA
$240.74
▲+0.77%
SPCX
$173.72
▲+1.54%
MU
$1,067.79
▲+0.36%
MRVL
$286.85
▲+5.75%
AMD
$655.72
▲+3.79%
SNDK
$1,677.16
▼-1.58%
AVGO
$378.71
▲+4.47%
INTC
$113.16
▼-2.61%
NVDA
$240.74
▲+0.77%
SPCX
$173.72
▲+1.54%
MU
$1,067.79
▲+0.36%
MRVL
$286.85
▲+5.75%
AMD
$655.72
▲+3.79%
SNDK
$1,677.16
▼-1.58%
AVGO
$378.71
▲+4.47%
INTC
$113.16
▼-2.61%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Fortrea Holdings Inc. - Common Stock
(NQ:
FTRE
)
21.60
+0.49 (+2.32%)
Delayed Quote
Updated: 12:33 PM EDT, Oct 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Fortrea Holdings Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Q4 Earnings Highs And Lows: Fortrea (NASDAQ:FTRE) Vs The Rest Of The Drug Development Inputs & Services Stocks
March 03, 2026
Via
StockStory
Fortrea (FTRE) Q4 2025 Earnings Call Transcript
↗
February 26, 2026
Fortrea (FTRE) Q4 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Fortrea Holdings Inc (NASDAQ:FTRE) Reports Mixed Q4 2025 Results and Cautious 2026 Outlook
↗
February 26, 2026
Via
Chartmill
Fortrea (NASDAQ:FTRE) Reports Sales Below Analyst Estimates In Q4 CY2025 Earnings
February 26, 2026
Clinical research company Fortrea Holdings (NASDAQ:FTRE) fell short of the market’s revenue expectations in Q4 CY2025, with sales falling 5.2% year on year to $660.5 million. The company’s full-year...
Via
StockStory
Fortrea Reports Fourth Quarter and Full-Year 2025 Results; Issues Full-Year 2026 Guidance
February 26, 2026
From
Fortrea Holdings Inc
Via
GlobeNewswire
Earnings To Watch: Fortrea (FTRE) Reports Q4 Results Tomorrow
February 25, 2026
Clinical research company Fortrea Holdings (NASDAQ:FTRE) will be announcing earnings results tomorrow morning. Here’s what to expect.
Via
StockStory
Topics
Artificial Intelligence
iRhythm, agilon health, GoodRx, Fortrea, and Myriad Genetics Stocks Trade Down, What You Need To Know
February 23, 2026
A number of stocks fell in the morning session after the Trump administration's announcement of new global tariffs reignited trade policy uncertainty. The move came swiftly after the Supreme Court...
Via
StockStory
Topics
Government
World Trade
1 Russell 2000 Stock to Target This Week and 2 That Underwhelm
February 19, 2026
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the...
Via
StockStory
3 Reasons to Sell FTRE and 1 Stock to Buy Instead
February 18, 2026
Over the past six months, Fortrea has been a great trade, beating the S&P 500 by 28.1%. Its stock price has climbed to $10.64, representing a healthy 34.8% increase. This was partly due to its solid...
Via
StockStory
Topics
Stocks
Fortrea Expands Executive Team, Appointing Oren Cohen as Chief Medical Officer and Scott Dove as President of Clinical Pharmacology Services
February 17, 2026
Adds to executive focus on early clinical development and deepens medical and scientific partnership with clients
From
Fortrea Holdings Inc
Via
GlobeNewswire
Fortrea Announces Date for Fourth Quarter and Full Year 2025 Financial Results and Conference Call
January 29, 2026
From
Fortrea Holdings Inc
Via
GlobeNewswire
2 Unprofitable Stocks with Promising Prospects and 1 We Turn Down
January 18, 2026
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, these businesses risk running out of capital...
Via
StockStory
Why Fortrea (FTRE) Stock Is Trading Up Today
January 16, 2026
Shares of clinical research company Fortrea Holdings (NASDAQ:FTRE) jumped 4.8% in the afternoon session after Evercore ISI upgraded the stock to Outperform from In Line and significantly raised its...
Via
StockStory
Topics
Artificial Intelligence
Initial Public Offering
Supply Chain
Fortrea Announces Updated Presentation Time at Upcoming J.P. Morgan Healthcare Conference
January 09, 2026
From
Fortrea Holdings Inc
Via
GlobeNewswire
Fortrea to Present at Upcoming J.P. Morgan Healthcare Conference
January 06, 2026
From
Fortrea Holdings Inc
Via
GlobeNewswire
3 Small-Cap Stocks Walking a Fine Line
January 05, 2026
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a...
Via
StockStory
3 Unpopular Stocks We Steer Clear Of
December 30, 2025
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps...
Via
StockStory
3 Inflated Stocks with Open Questions
December 28, 2025
Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or...
Via
StockStory
3 Stocks Under $50 Walking a Fine Line
December 24, 2025
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to...
Via
StockStory
Why Fortrea (FTRE) Stock Is Up Today
December 19, 2025
Shares of clinical research company Fortrea Holdings (NASDAQ:FTRE) jumped 8% in the afternoon session after an analyst at Mizuho raised the firm's price target on the stock while maintaining a Neutral...
Via
StockStory
Topics
Initial Public Offering
Why Fortrea (FTRE) Stock Is Trading Up Today
December 18, 2025
Shares of clinical research company Fortrea Holdings (NASDAQ:FTRE) jumped 5.7% in the morning session after an analyst at Mizuho raised the company's price target. Analyst Ann Hynes reaffirmed a...
Via
StockStory
Topics
Initial Public Offering
Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. (NASDAQ: FTRE); Molina Healthcare, Inc. (NYSE: MOH); and Synopsys, Inc. (NASDAQ: SNPS): Grabar Law Office Investigates Claims on Your Behalf
December 16, 2025
From
Grabar Law Office
Via
GlobeNewswire
Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. (NASDAQ: FTRE); Synopsys, Inc. (NASDAQ: SNPS); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf
December 12, 2025
From
Grabar Law Office
Via
GlobeNewswire
Why Fortrea (FTRE) Stock Is Up Today
December 11, 2025
Shares of clinical research company Fortrea Holdings (NASDAQ:FTRE) jumped 6.2% in the afternoon session after Citigroup upgraded the stock's rating to Buy from Neutral and significantly raised its...
Via
StockStory
Topics
Artificial Intelligence
Initial Public Offering
Important Notice to Long-Term Shareholders of Alexandria Real Estate Equities, Inc. (NYSE: ARE); CarMax, Inc. (NYSE: KMX); Fortrea Holdings, Inc. (NASDAQ: FTRE); StubHub Holdings, Inc. (NYSE: STUB): Grabar Law Office Investigates Claims on Your Behalf
December 11, 2025
From
Grabar Law Office
Via
GlobeNewswire
Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
December 10, 2025
From
Fortrea Holdings Inc
Via
GlobeNewswire
Attention Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. (NASDAQ: FTRE); Synopsys, Inc. (NASDAQ: SNPS); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf
December 08, 2025
From
Grabar Law Office
Via
GlobeNewswire
SCTbio and Fortrea Forge Strategic Collaboration to Accelerate Cell and Gene Therapy Development and Delivery
December 04, 2025
From
Fortrea Holdings Inc
Via
GlobeNewswire
Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. (NASDAQ: FTRE); Unicycive Therapeutics, Inc. (NASDAQ: UNCY); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office is Investigating Claims
December 02, 2025
From
Grabar Law Office
Via
GlobeNewswire
Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. (NASDAQ: FTRE); Ibotta, Inc. (NYSE: IBTA); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office is Investigating Claims on Your Behalf
December 01, 2025
From
Grabar Law Office
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
